| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 144 |
| 16 Nov 2026 | 144 |
| 13 Nov 2026 |
Form 4: Azar Alex M Ii, Director
Received 138 shares by exercise or conversion |
| 13 Nov 2026 |
Form 4: Sayer Kevin R, Director
Granted 3,149 Restricted Stock Units |
| 12 Nov 2026 |
Form 3: Sayer Kevin R, Director
Holds 0 shares of Common Stock |
| 12 Nov 2026 |
Form 4: Parks Robert, Chief Accounting Officer
Granted 18,893 Restricted Stock Units |
| 12 Nov 2026 |
Form 3: Parks Robert, Chief Accounting Officer
Holds 0 shares of Common Stock |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Third quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening |
| 05 Nov 2026 | SCHEDULE 13G |
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
PALO ALTO, Calif., — November 3, 2026 — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and curre... |
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Performance-Based Restricted Stock Units (the “PSUs”) described in this Global Performance-Based Restricted St... |
| 22 Oct 2026 |
Form 4: Mignone Roberto, Director
Received 264 shares by exercise or conversion |
| 19 Oct 2026 |
Form 4: Hidalgo Medina Manuel, Director
Received 232 shares by exercise or conversion |
| 19 Oct 2026 |
Form 4: Tariq Musa, Director
Received 250 shares by exercise or conversion · Sold 116 shares ($19.2K) |
| 16 Oct 2026 | 144 |
| 15 Oct 2026 |
Form 4: Azar Alex M Ii, Director
Sold 69 shares ($11K) |
| 14 Oct 2026 | 144 |
| 13 Oct 2026 |
Form 4: Azar Alex M Ii, Director
Received 137 shares by exercise or conversion |
| 02 Oct 2026 |
Form 4: Saia John G., Chief Legal Officer
Received 7,063 shares by exercise or conversion · Gave up 3,706 shares to cover exercise price or tax ($648K) |
Loading...